HeartBeam Launches New Video Showcasing The HeartBeam AIMI™ And AIMIGo™ Applied sciences
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac expertise firm that has developed the primary and solely 3D-vector ECG platform for coronary heart assault detection anytime, anyplace, at present introduced that together with an upcoming digital roadshow webinar happening Tuesday, September 20, 2022, at 4:30 p.m. ET, it has launched a brand new video that takes viewers behind the scenes for a featured have a look at the HeartBeam AIMIGo expertise and can be proven to viewers of the webcast.
The video explores the HeartBeam AIMIGo expertise, want, market alternative and use in coronary heart assault detection. AIMIGo is the primary and solely credit score card-sized 12-lead output ECG gadget for distant coronary heart assault detection with a 510(Ok) regulatory pathway. The Firm expects to submit AIMIGo to the US Meals and Drug Administration (FDA) for clearance by the tip of the yr. As soon as cleared the Firm believes that AIMIGo can allow sufferers and their clinicians, for the primary time outdoors of a medical setting, to find out if signs are because of a coronary heart assault, rapidly and simply, so care might be initiated, if wanted. The objective of HeartBeam’s expertise is to supply extra correct coronary heart assault detection to triage sufferers, expedite remedy and save healthcare {dollars}.
The video is out there within the firm’s investor relations part right here.
“This new video offers a compelling overview and rationalization of our applied sciences and highlights our continued progress towards making the AIMIGo gadget obtainable for distant coronary heart assault detection,” stated Branislav Vajdic, PhD, HeartBeam CEO and founder. “We look ahead to sharing the video at our upcoming webinar together with current bulletins, ongoing initiatives and key 2022 and 2023 milestones.”
HeartBeam’s CEO and founder Branislav Vajdic, PhD, CFO Rick Brounstein, and Chief Enterprise Officer Jon Hunt, PhD, will host a digital roadshow webinar, throughout which they’ll overview current bulletins, together with the Firm’s 510(ok) utility to the FDA for its HeartBeam AIMI platform expertise, newly issued patent for a 12-lead electrocardiogram (ECG) patch monitor, ongoing initiatives and talk about key 2022 and 2023 milestones. The webinar can be accompanied by a presentation and adopted by a question-and-answer session from webcast viewers, which might be accessed by way of the webcast hyperlink.
HeartBeam AIMI and AIMIGo haven’t but been cleared by the FDA for advertising within the USA or different geographies.
To entry the webinar, please use the next info:
A phone replay can be obtainable roughly two hours after the decision and can run by way of December 20, 2022, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from worldwide places, and getting into replay pin quantity: 13732771. The replay may also be seen by way of the webinar webcast hyperlink above and the presentation utilized throughout the name can be obtainable within the firm’s investor relations part right here.
